Drug intelligence / Profile preview

epstein-barr virus-specific stem cell memory cytotoxic T lymphocytes

Development stage: Phase 2
Lead developer: Baylor College of Medicine
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Epstein-Barr virus-specific stem cell memory cytotoxic T lymphocytes (EBV-specific T_SCM-enriched T cells) represent an advanced form of adoptive T-cell therapy. This therapy involves the ex vivo expansion of a patient's or donor's T cells, specifically enriching for those with a stem cell memory (T_SCM) phenotype that are specific to Epstein-Barr virus (EBV) antigens. T_SCM cells are characterized by superior self-renewal capacity, robust engraftment, prolonged persistence, and enhanced anti-cancer efficacy compared to more differentiated T-cell subsets. The primary mechanism of action is to restore or augment the immune system's ability to recognize and eliminate EBV-infected cells, which are often implicated in various malignancies and post-transplant lymphoproliferative disorders (PTLD). This approach aims to provide long-lasting immunity and therapeutic effect against EBV-associated diseases.

Other names: EBV-specific T_SCM-enriched T cells

Targets

EBNA1 (Epstein-Barr virus latency proteins)

Beyond the preview

Go deeper on epstein-barr virus-specific stem cell memory cytotoxic T lymphocytes.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epstein-barr virus-specific stem cell memory cytotoxic T lymphocytes.

Explore the full profile